The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Cited by (390)

Items 201–300 of 390

1. Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer
   Agostino Palladino, Matthew F. W. Gee, Victoria Shalhoub, David Kiaei · 2023 · Clinica Chimica Acta
2. Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
   Mohamed El‐Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab · 2024 · Seminars in Liver Disease
3. Knockdown of Hyaluronan synthase 2 suppresses liver fibrosis in mice via induction of transcriptomic changes similar to 4MU treatment
   Noreen Halimani, Mikhail V. Nesterchuk, Alexandra A. Tsitrina, Marat S. Sabirov, Irina N. Andreichenko, Nataliya O. Dashenkova, Elizaveta Petrova, А. М. Куликов, Timofei S. Zatsepin, Roman A. Romanov et al. · 2024 · Scientific Reports
4. The role of fibrosis in cardiomyopathies: An opportunity to develop novel biomarkers of disease activity
   Elisavet Angeli, Maria Jordan, Mandy Otto, Stevan D. Stojanović, M.A. Karsdal, Johann K Bauersachs, Thomas Thum, Jan Fiedler, Federica Genovese · 2024 · Matrix Biology
5. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease
   Monica A. Tincopa, Rohit Seth Loomba · 2024 · Seminars in Liver Disease
6. Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
   Alessandro Mantovani, Giovanni Targher, Giacomo Zoppini · 2020 · Clinics in Geriatric Medicine
7. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
   Vinka Rupčić Rubin, Kristina Bojanić, Martina Smolić, Jurica Rubin, Ashraf Abdou Tabll, Robert Smolić · 2021 · Journal of Clinical and Translational Hepatology
8. Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH
   Xiaoxiao Wang, Zilong Wang, Baiyi Liu, Rui Jin, Yuyun Song, Ran Fei, Cong Xu, Rui Huang, Xiaohe Li, Jia Ni Yang et al. · 2023 · Frontiers in Immunology
9. The Liver in Diabetes and Metabolic Syndrome
   Mia C. Mahmoud, Manal F. Abdelmalek · 2025 · Clinics in Liver Disease
10. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review
    Marcio José Concepción‐Zavaleta, Jenyfer María Fuentes‐Mendoza, Jhean Gabriel Gonzáles Yovera, Gemma Y Ruvalcaba-Barbosa, Leonardo D Cura-Rodríguez, Josué S González-Rodríguez, Luis Alberto Concepción Urteaga, Aranza I Pérez-Reyes, Juan Eduardo Quiroz Aldave, José Paz‐Ibarra · 2025 · World Journal of Gastroenterology
11. MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    David Yardeni, Adi Shiloh, Inna Lipnizkiy, Anat Nevo-Shor, Naim Abu‐Freha, Daniela Munteanu, Victor Novack, Ohad Etzion · 2023 · Scientific Reports
12. Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology
    Nikolai V. Naoumov, David Erwin Kleiner, Elaine Chng, Dominique Brees, Chandrassegar Saravanan, Yayun Ren, Dean Tai, Arun Jayant Sanyal · 2024 · Liver International
13. Natural small molecule hinokitone mitigates NASH fibrosis by targeting regulation of FXR-mediated hepatocyte apoptosis
    Ze-Jiang Ma, Ying‐Kun Qiu, Zhe-Wei Yu, Tiantian Song, Yitong Hu, Ankang Peng, Rong Qi · 2024 · Journal of Advanced Research
14. Preventing the progression of cirrhosis to decompensation and death
    Càndid Villanueva, Dhiraj Tripathi, Jaime Bosch · 2025 · Nature Reviews Gastroenterology & Hepatology
15. Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review
    Xiaoyu Xie, Amine Benmassaoud · 2025 · World Journal of Hepatology
16. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis
    Kanehiko Suwa, Takashi Yamaguchi, Katsunori Yoshida, Miki Murata, Mayuko Ichimura‐Shimizu, Koichi Tsuneyama, Toshihito Seki, Kazuichi Okazaki · 2020 · Cancers
17. Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis
    Jesús Rivera‐Esteban, Angelo Armandi, Salvador Augustín, Elisabetta Bugianesi · 2021 · Liver International
18. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study
    Fernanda Kreve, Guilherme Hoverter Callejas, Laísa Simakawa Jimenez, Rodolfo Araújo Marques, Felipe David Mendonça Chaim, Murillo Pimentel Utrini, Martinho Antônio Gestic, Almino Cardoso RAMOS, Elinton Adami Chaim, Everton Cazzo · 2022 · Sao Paulo Medical Journal
19. Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions
    Venkateswararao Eeda, Nikhil Y. Patil, Aditya Dilip Joshi, Vibhudutta Awasthi · 2023 · Hepatology Research
20. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a western perspective
    Ann Farrell, Marno Celeste Ryan, Jessica A. Howell · 2020 · Hepatoma Research
21. Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression
    Carlota Tuero, Sara Becerril, Silvia Ezquerro, Gabriela Neira, Gema Frühbeck, Amaia Rodrı́guez · 2022 · Journal of Physiology and Biochemistry
22. Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis
    Yang Zhi, Yinuo Dong, Xiaoyun Li, Wei Zhong, Xiaohong Lei, Jie Ting Tang, Yimin Mao · 2024 · Diabetes/Metabolism Research and Reviews
23. Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study
    Cheng-Cheng Tong, Yufeng Xue, Wei Wang, Xi Chen · 2024 · BMC Public Health
24. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
    Shraddha Shinde, David R. Nelson, Jessica Mitroi, Pamela C. Heaton, Ana L. Hincapie, Bram Brouwers · 2023 · Current Medical Research and Opinion
25. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma
    Antonio Saviano, Natascha Roehlen, Thomas F. Baumert · 2024 · Seminars in Liver Disease
26. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes
    Alshaima Alhinai, Keyur Patel, Vivian Andrew Fonseca, Giada Sebastiani · 2021 · Journal of Diabetes and its Complications
27. Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy
    Charalampos G. Pontikoglou, Theodosios D. Filippatos, Angelos Matheakakis, Helen Α. Papadaki · 2024 · Metabolism
28. Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
    Brian P Lam, Jessica Bartholomew, Sherona Bau, HoChong Gilles, Andrea Keller, Ann Moore, Khalil Nader, Lisa Richards, Linda L Henry, Zobair M. Younossi · 2025 · Journal of Clinical Gastroenterology
29. Diagnostic Accuracy of the LiverRisk Score to Detect Increased Liver Stiffness Among a United States General Population and Subgroups
    Laurens A. van Kleef, Jesse Pustjens, Harry L.A. Janssen, Willem Pieter Brouwer · 2025 · Journal of Clinical and Experimental Hepatology
30. Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and Death in NAFLD
    Emily Truong, Lynna Alnimer, JEFFREY A. GORNBEIN, Ju Dong Yang, Naim Alkhouri, Stephen A. Harrison, Mazen Noureddin · 2025 · Digestive Diseases and Sciences
31. EUS-guided portal pressure gradient measurement for evaluating the severity of portal hypertension: A retrospective analysis
    Rongkun Luo, Mingcong Chen, LU Huan-yuan, Rui Zhang, Hongwu Luo, Ying‐Hong Liu, Xunyang Liu, Feizhou Huang, Gang Deng, Zhao Lei · 2025 · Endoscopic Ultrasound
32. Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation
    Sonia Samuel, Ahmad Abulawi, Raza Malik · 2023 · Gastroenterology Insights
33. Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in Germany
    Christian Markus Lange, Jonel Trebicka, Alexander L. Gerbes, Ali E. Canbay, Andreas Geier, Uta Merle, Markus Peck‐Radosavljevic, Frank Tacke, Tobias Vogelmann, Sina Theis et al. · 2023 · Liver International
34. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry
    Amon Asgharpour, Amreen M. Dinani, Scott L. Friedman · 2020 · Translational Gastroenterology and Hepatology
35. Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis
    Dhanpat Jain, Prithvi Sreenivasan, Irteza Inayat, Yanhong Deng, Maria M. Ciarleglio, Guadalupe García–Tsao · 2021 · American Journal of Clinical Pathology
36. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
    Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez M. Zannad, Arun Jayant Sanyal · 2021 · Diabetes & Metabolism
37. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study
    Octavi Bassegoda, Jesús Rivera‐Esteban, Isabel Serra, Rosa Maria Morillas, Teresa Broquetas, Mercedes Vergara, Adrià Rodríguez-Castellano, Carles Aracil, Silvia Virolés, José Antonio Carrión et al. · 2022 · Hepatology Communications
38. The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention
    Chuan Liu, Yanna Liu, Ruoyang Shao, Sining Wang, Guangchuan Wang, Lifen Wang, Mingyan Zhang, Jinlin Hou, Chunqing Zhang, Xiaolong Qi · 2020 · Annals of Translational Medicine
39. A Primer to the Diagnostic and Clinical Utility of Spleen Stiffness Measurement in Patients With Chronic Liver Disease
    Andrea Mladenovic, Raj Vuppalanchi, Archita P. Desai · 2022 · Clinical Liver Disease
40. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
    Elliot B. Tapper, Charlotte Fleming, Adriana Rendon, João Diogo da Rocha Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair · 2022 · Gastro Hep Advances
41. Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Arka De, Naga Chalasani, Ajay Kumar. Duseja · 2025 · Gastroenterology Clinics of North America
42. Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD : A Systematic Review and Meta‐Analysis
    Rachael Barrett, Ann Jane Archer, Jennifer Cathcart, Kushala W. M. Abeysekera, John Francis Dillon, Paul Brennan · 2026 · Liver International
43. Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review
    Brian J. Wentworth · 2024 · Metabolism and Target Organ Damage
44. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg
    Ankur Jindal, Shiv Kumar Sarin, Manoj Kumar, Guresh Kumar · 2022 · Digestive Diseases and Sciences
45. Advances in fibrosis biomarkers in nonalcoholic fatty liver disease
    Stefano Ciardullo, Gianluca Perseghin · 2022 · Advances in clinical chemistry
46. Quantitative image-based collagen structural features predict the reversibility of hepatitis C virus-induced liver fibrosis post antiviral therapies
    Laurent Golé, Feng Liu, Kok Haur Ong, Longjie Li, Hao Han, David Matthew Young, Gabriel Pik Liang Marini, Aileen Wee, Jingmin Zhao, Huiying Rao et al. · 2023 · Scientific Reports
47. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
    Albert Do, Ysabel C. Ilagan‐Ying, Wajahat Zafar Mehal, Joseph K. Lim · 2020 · Expert Opinion on Drug Discovery
48. Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural
    Jhon Edison Prieto Ortíz, Carlos Bernardo Sánchez Luque, Rolando José Ortega Quiróz · 2022 · Revista Colombiana de Gastroenterología
49. Perceptions, Attitudes, Beliefs, and Practices Toward Traditional Chinese Medicine Therapies for Herpes Zoster: A Cross-Sectional Study of Healthcare Professionals
    Jiani Wang, Liudan Chen, Zhuangfei Wang, Xiaohong Fang, Yan Zhen · 2024 · Risk Management and Healthcare Policy
50. Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH
    Matthew F. W. Gee, Rachel K. Fonstad, Edward B. De Vol, Chadwick Brown, Jordan J. Feld, Keyur Patel, Arun Jayant Sanyal · 2026 · Hepatology Communications
51. Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials
    Hsin-Tien Ho, Yu‐Lueng Shih, Tien‐Yu Huang, Wen‐Hui Fang, Chang-Hsien Liu, Jung‐Chun Lin, Chih–Weim Hsiang, Kai‐Min Chu, Cheng-Huei Hsiong, Guan-Ju Chen et al. · 2024 · Journal of Translational Medicine
52. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
    James Phillip Esteban, Amon Asgharpour · 2020 · Gastroenterology Clinics of North America
53. Liver Transplant Outcomes in Young Adults with Cirrhosis Related to Nonalcoholic Fatty Liver Disease
    Dmitri S. Bezinover, Naim Alhkouri, Roman Schumann, Nathaniel R. Geyer, Vernon M. Chinchilli, Jonathan G. Stine · 2023 · Transplantation Proceedings
54. Hepatocellular Carcinoma in Non-Fibrotic Liver: A Narrative Review
    Hiroko Naganuma, Hideaki Ishida · 2023 · Diagnostics
55. Hipertensión portal: recomendaciones de diagnóstico y tratamiento. Documento de consenso de la Asociación Española para el Estudio del Hígado (AEEH) y el Centro para la Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
    Agustı́n Albillos, Rafael Bañares, Virginia Hernández–Gea, Edilmar Alvarado‐Tápias, Javier Ampuero, Anna Baiges, Pablo Bellot, José Luis Calleja, Andrés Cárdena, María-Vega Catalina et al. · 2024 · Gastroenterología y Hepatología
56. Hepatic venous pressure gradient and rebleeding risk of patients with nonalcoholic steatohepatitis cirrhosis after variceal bleeding
    Yiqi Shi, Wenyong Shen, Gang Xu, Xunzheng Wang, Bo Ning · 2023 · Frontiers in Medicine
57. Global, regional, and national burden of primary liver cancer among middle-aged and elderly populations from 2000 to 2021 with a prediction to 2050: a cross-sectional analysis from Global Burden of Disease Study 2021
    Wei Wang, Yongqiang Xiong, Na Huang, Jun Li, Shu Zhang · 2025 · International Journal of Surgery
58. Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis
    Francisco Javier Idalsoaga, Luis Antonio Díaz, Saleh A. Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Kieu Ha, Jessica Le, John K MacDonald et al. · 2025 · Clinical Gastroenterology and Hepatology
59. Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy
    Rong Fu, Fuyuan Zhang, Junliang Fu, Yuqian Li, Xiangming Zhu, Qian Ding, Yi Zhun Zhu · 2025 · Metabolism and Target Organ Damage
60. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
    Willem Pieter Brouwer, Luisa Vonghia, Maja Sofie Thiele, Jörn Markus Schattenberg, Foteini Anastasiou, Sonja Beckmann, Elisabetta Bugianesi, Laurent Castéra, Cyrielle Caussy, Ahmed Cordie et al. · 2026 · JHEP Reports
61. Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
    Eliabe S. Abreu, Mazen Noureddin, Hirokazu Takahashi, Jörn Markus Schattenberg, Manal F. Abdelmalek · 2026 · Clinics in Liver Disease
62. MASLD and the cardiovascular-kidney-liver-metabolic syndrome
    Angeliki M. Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P. Mikhailidis, George Jacob, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
63. Optical imaging unveils morphological heterogeneity at the hepatic lobule level during metabolic dysfunction-associated fatty liver disease progression [Invited]
    Qi Zhou, Jiao Liu, Honghui Li, Aoji Qin, Liming Nie · 2025 · Biomedical Optics Express
64. Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis
    Christian Labenz, Gerrit Toenges, Ming‐Hua Zheng, Dora Ding, Robert P. Myers, Peter R. Galle, Angelo Armandi, Javier Ampuero, Manuel Romero‐Gómez, Elisabetta Bugianesi et al. · 2022 · European Journal of Internal Medicine
65. Liver fibrosis for the dermatologist: a review
    Mina M Raahimi, Amy Livesey, Jessica Hamilton, Alexa Rose Shipman, Richard Aspinall · 2022 · Clinical and Experimental Dermatology
66. Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
    Yuan Yao, Yunfeng Shen · 2023 · Open Life Sciences
67. Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine Learning
    Jörn Markus Schattenberg, Maria‐Magdalena Balp, Brenda Reinhart, Sanchita Porwal, Andreas Tietz, Marcos C. Pedrosa, Matt Docherty · 2023 · Gastro Hep Advances
68. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina · 2024 · Metabolism and Target Organ Damage
69. Assessing Clinician Engagement With a Passive Clinical Decision Support System for Liver Fibrosis Risk Stratification in a Weight Management Clinic
    Arpan Mohanty, Kirsten Austad, Nicholas A. Bosch, Michelle T. Long, Eric Nolen‐Doerr, Allan J. Walkey, Mari‐Lynn Drainoni, Ivania M. Rizo, Kathryn L. Fantasia · 2025 · Endocrine Practice
70. Dynamic changes in the characteristics of hepatocellular carcinoma among Japanese patients: Increasing incidence of cases without liver fibrosis
    Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, Yuka Kimura, Ayaka Nakamura, Kana Matsuoka, Takuya Matsuda, Kanako Kato, Kazuya Murakawa, Kei Onishi et al. · 2025 · Hepatology Research
71. HVPG as a Gold Standard: Accuracy Is Essential
    Juan Carlos García‐Pagán, Filippo Schepis, Ron Charles Gaba, Alberto Zanetto, Valeria Pérez‐Campuzano, Ziv J. Haskal, Héctor Ferral · 2022 · Springer eBooks
72. The prediction of liver decompensation using hepatic collagen deposition assessed by computer-assisted image analysis with Masson’s trichrome stain
    Hae Won Yoo, Jae Woo Park, Min-Jung Jung, Jeong‐Ju Yoo, Sang Gyune Kim, Young Seok Kim · 2023 · Scandinavian Journal of Gastroenterology
73. Cardiometabolic risk factors and clinical course of liver cirrhosis
    Michele Esposito, Raffaele Buono, Paolo Angeli, Paolo Girardi, Marco Di Pascoli · 2024 · Digestive and Liver Disease
74. Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro‐Narro · 2025 · Expert Review of Gastroenterology & Hepatology
75. Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis
    Laura Buttler, Anja Tiede, Marie Griemsmann, Hannah Rieland, Jim Benjamin Mauz, Heiner H. Wedemeyer, Markus Cornberg, Tammo Lambert Tergast, Katharina Luise Hupa‐Breier, Benjamin Maasoumy · 2025 · PLoS ONE
76. Assessment and management of portal hypertension in patients with MASLD: advances and caveats
    Diego Rojo, Alba Jiménez-Masip, Laura Pagès, Juan Bañares, Clara Sabiote, María Martínez-Gómez, Laia Aceituno, M Serra Cusidó, M. Teresa Salcedo-Allende, Zyanya Calixto et al. · 2025 · Expert Review of Gastroenterology & Hepatology
77. GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH
    María Andrés‐Rozas, Zoe Boyer‐Díaz, Eugènia Ruiz-Cánovas, Peio Aristu-Zabalza, Sergi Guixé‐Muntet, Cristina Fernández-Asensio, Juan José Lozano, Noemı́ Garcı́a-Delgado, Carla Fuster, Jaume Mercadé et al. · 2025 · JHEP Reports
78. Global, regional, and national burdens of non-alcoholic fatty liver disease attributable to smoking from 1990 to 2021
    Pengyue Zhang, Jie Zhu, Xi Chen, Chunhui Tao, Jianmei Zhou, Zhenhua Zhang, Xiaodan Hong · 2025 · Ecotoxicology and Environmental Safety
79. Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs
    Eda Kaya, Yusuf Yilmaz, Naim Alkhouri · 2025 · Expert Opinion on Pharmacotherapy
80. Fibrosis activity vs. disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease
    Stine Johansen, Mads Egerod Israelsen, Katrine Holtz Thorhauge, Johanne Kragh Hansen, Camilla Dalby Hansen, Helle Lindholm Schnefeld, Peter Andersen, Ida Falk Villesen, K. Bech, Sönke Detlefsen et al. · 2026 · JHEP Reports
81. Vi trenger en ny strategi for leversykdom
    Mette Nåmdal Vesterhus, Kristin Kaasen Jørgensen, Svein Oskar Frigstad, John Willy Haukeland, Tom H. Karlsen · 2022 · Tidsskrift for Den norske legeforening
82. Novel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
    F. Amato, Martina Marano, Kamela Gjini, Lorenza VAIRA, Elisabetta Bugianesi, Angelo Armandi · 2024 · Minerva Biotechnology and Biomolecular Research
83. Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease
    Buket Yiğit, Ekin Özgönül, Omer Yaman, Tarık Sipahioglu, Bürge Ulukan, Yağmur Çetin Taş, Berna Morova, Musa Aydın, Yiğit Uysallı, Elif Demirtas et al. · 2025 · Scientific Reports
84. Insight into increased risk of portal vein thrombosis in nonalcoholic fatty liver disease
    Hang Gong, Huang Zhong, Huimei Xu, Xiong-Chang Liu, LI Liang-ping, Dekui Zhang · 2023 · European Journal of Internal Medicine
85. Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
    Gourdas Choudhuri, Saumin Shah, Anand V. Kulkarni, Nitin Jagtap, Pratyusha Prakash Gaonkar, Akshay Suvas Desai, Charles V Adhav · 2023 · Cureus
86. Three-dimensional magnetic resonance elastography combining proton-density fat fraction precisely identifies metabolic dysfunction-associated steatohepatitis with significant fibrosis
    Huimin Lin, Suhao Qiu, Yanzhao Yang, Chunxue Yang, Zhehan Shen, Yu Chen, Zhihan Zhang, Yuan Feng, Fuhua Yan · 2023 · Magnetic Resonance Imaging
87. Impact of catheter tip to hepatic vein ostium distance on the validity and prognostication of hepatic venous pressure gradient in cirrhosis
    Hiang Keat Tan, Alfred Bingchao Tan, Kevin Kim‐Jun Teh, Apoorva Gogna, Chow Wei Too, Sum Leong, Jason Pik-Eu Chang · 2023 · Scientific Reports
88. Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals
    Sheng‐Hung Chen, Hsueh‐Chou Lai, Wen‐Pang Su, Jung‐Ta Kao, Wei‐Fan Hsu, Hung‐Wei Wang, Hung‐Yao Chen, Cheng‐Yuan Peng · 2024 · Journal of the Formosan Medical Association
89. An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease
    Shahid Habib, Andrew Johnson · 2024 · Exploration of Digestive Diseases
90. Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study
    Yestle Kim, Joseph J. Medicis, Matthew R. Davis, Dominic Nunag, Robert Gareth Gish · 2024 · Journal of Comparative Effectiveness Research
91. Derivation and validation of Transform equations to convert historical Enhanced liver fibrosis (ELF) scores to modern equivalents
    Matthew F. W. Gee, Agostino Palladino, H. Roma Levy, Edward Bentz Devol, David Kiaei · 2023 · Clinica Chimica Acta
92. Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd)
    Agustı́n Albillos, Rafael Bañares, Virginia Hernández–Gea · 2024 · Gastroenterología y Hepatología (English Edition)
93. The use of ELF in predicting liver fibrosis prevalence and fibrosis progression in the general population
    Kustaa Saarinen, Martti A. Färkkilä, Antti Jula, Iris Erlund, Terhi Vihervaara, Annamari Lundqvist, Fredrik O. Åberg · 2025 · Scandinavian Journal of Gastroenterology
94. Inhibiting peripheral serotonin activates liver AMPK and reduces monocyte-derived macrophages and fibrosis
    Battsetseg Batchuluun, Tinne Thoné, Andre Djalalvandi, Russta Fayyazi, Parneet Deo, Julian M. Yabut, Sara Maggiore, Bavo Vanneste, Jaya Gautam, Logan K. Townsend et al. · 2025 · Cell Reports
95. Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden
    Ying Shang, Linnea Widman, X. Zhang, Gail F. Fernandes, Matthew G. Melaragno, Samuel S. Engel, Johan Vessby, Mattias Ekstedt, Hannes Hagström · 2025 · Liver International
96. MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD
    Christian Brion, Stephen Aurelien Hoang, Guangliang Wang, Faridodin Mirshahi, Jessie Ang, Matthew Long, Zheng Zhu, Bhanu Sakhamuri, Molly A. Srour, Mohammad Shadab Siddiqui et al. · 2025 · Clinical and Molecular Hepatology
97. Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
    Valeria Piazzolla, Antonio Napolitano, A. Mangia · 2025 · Metabolism and Target Organ Damage
98. Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan
    Yoshihiro Kamada, Yoshio Sumida, Hirokazu Takahashi, Hiroshi Ishiba, Miwa Kawanaka, Toshifumi Tada, Masato Yoneda, Kento Imajo, Yuya Seko, Hideki Fujii et al. · 2026 · World Journal of Gastroenterology
99. Sinusoidal cell–derived biomarker scores predict diagnosis and prognosis in chronic liver disease
    Sergi Guixé‐Muntet, Anabel Fernández‐Iglesias, David Lopez, Emilio Domingo Tonina, Yiliam Fundora, Anna Zagórska, Jordi Gracia‐Sancho · 2026 · BMC Medicine
100. Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials
     Samira Mohamad Khalil, Lubna Al‐Sharif, Ivanna Diaz, Matheus Henrique Gonçalves de Souza · 2026 · Digestive Diseases and Sciences